Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 6/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1154674 | 0.84 | DRD2 (0.37) | LMNASMN1; SMN2SLC6A4MEN1KMT2A | |
| SCHEMBL1155086 | 0.84 | HTR6 (0.40) | LMNACYP2D6SLC6A2SLC6A4ADRA2A | |
| SCHEMBL1155061 | 0.84 | HTR6 (0.40) | LMNACYP2D6SLC6A2SLC6A4ADRA2A | |
| SCHEMBL1154472 | 0.84 | HTR6 (0.40) | LMNACYP2D6SLC6A2SLC6A4ADRA2A | |
| SCHEMBL1154833 | 0.83 | HTR6 (0.46) | SLC6A4ADRA2AADRA2BADRA2C | |
| SCHEMBL1154809 | 0.82 | CASR (0.41) | MEN1RAB9AKMT2ACASR | |
| SCHEMBL1154713 | 0.82 | SLC6A4 (0.40) | CYP2D6SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL1155239 | 0.81 | HTR6 (0.37) | LMNASLC6A4ADRA2AADRA2BADRA2C | |
| SCHEMBL1155306 | 0.81 | ALDH1A1 (0.37) | MEN1KMT2ACASR | |
| SCHEMBL1154564 | 0.81 | HTR6 (0.35) | LMNASLC6A4ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3121176-A1 | 2,4-DIAMINOQUINAZOLINES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | Families of Spinal Muscular Atrophy (US) | 2017-01-25 | — | — | EP | disclosed |
| EP-1765810-B1 | 2,4-DIAMINOQUINAZOLINES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2514748-B1 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160152577-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-06-02 | — | — | US | disclosed |
| US-9067897-B2 | 2,4-Diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2514748-A1 | 2,4-diaminoquinazolines for spinal muscular atrophy | Families of Spinal Muscular Atrophy (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20110112118-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-05-12 | — | — | US | disclosed |
| US-7888366-B2 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-02-15 | — | — | US | disclosed |
| EP-1765810-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | Decode Chemistry, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123724-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | DECODE CHEMISTRY, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050288314-A1 | 2,4-diaminoquinazolines for spinal muscular atrophy | DECODE CHEMISTRY, INC. (US) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112118-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | SMN1; SMN2, MUSK, MYO3B | LMNA 523/4885TP53 4864/4885SMN1; SMN2 1/4885 |
| US-20160152577-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | SMN1; SMN2, MUSK, MYO3B | LMNA 523/4885TP53 4864/4885SMN1; SMN2 1/4885 |
| US-20050288314-A1 | 2,4-diaminoquinazolines for spinal muscular atrophy | SMN1; SMN2, MUSK, MYO3B | LMNA 523/4885TP53 4864/4885SMN1; SMN2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.